Commercial Aquaculture Vaccine Market
Commercial Aquaculture Vaccine Market Study by Inactivated, Attenuated, Subunit, and DNA for Fish Farming Companies, Fish Veterinary Clinics, and Aquatic Research Institutes from 2024 to 2034
Analysis of Commercial Aquaculture Vaccine Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Commercial Aquaculture Vaccine Market Outlook (2024 to 2034)
According to the latest market study by seasoned analysts at Fact.MR, the global commercial aquaculture vaccine market size has been calculated at US$ 305.2 million for 2024 and is projected to expand at a CAGR of 6.7% and reach a size of US$ 584.3 million by 2034-end.
Commercial aquaculture vaccines are formulated to address specific pathogens that commonly affect farmed aquatic organisms. These pathogens include bacteria, viruses, and parasites that lead to diseases detrimental to the health and productivity of the aquaculture stocks. Different species within aquaculture, such as fish (e.g., salmon, tilapia), shrimp, and mollusks, may require distinct vaccine formulations. Manufacturers are focused on developing vaccines tailored to the unique immunological needs of each species.
- Salmon vaccine demand is forecasted to reach a market value of US$ 218.6 million by the end of 2034.
- Sales of trout vaccines are projected to increase at a CAGR of 7.2% through 2034.
Vaccines in aquaculture are administered through various methods, including immersion, injection, or oral delivery, depending on the characteristics of the target species and the nature of the vaccine.
- Sales of intraperitoneal aquaculture vaccine injections are predicted to reach US$ 355.5 million by 2034-end.
The primary goal of commercial aquaculture vaccines is to prevent diseases rather than treat them after an outbreak. Vaccination helps build immunity in aquatic organisms, reducing the risk of disease transmission and minimizing economic losses associated with mortalities and reduced growth rates.
- The North American commercial aquaculture vaccine market size is estimated at US$ 59 million in 2024 and is forecasted to reach US$ 115 million by 2034-end.
Supportive regulatory frameworks and respective government initiatives promoting responsible aqua farming are boosting the commercial aquaculture vaccine market growth in North America.
- Sales of commercial aquaculture vaccines in East Asia are projected to rise at a CAGR of 7.3% during the next 10 years.
| Report Attributes | Details |
|---|---|
| Commercial Aquaculture Vaccine Market Size (2024E) | US$ 305.2 Million |
| Forecasted Market Value (2034F) | US$ 584.3 Million |
| Global Market Growth Rate (2024 to 2034) | 6.7% CAGR |
| South Korea Market Value (2034F) | US$ 7 Million |
| Subunit Commercial Aquaculture Vaccine Demand Growth (2024 to 2034) | 8.4% CAGR |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Commercial Aquaculture Vaccine Market Trends are Set to Be Beneficial for Key Producers?
“Rising Need for Disease Prevention in Large-Scale Aquaculture Operations”
The commercial aquaculture pharmaceutical landscape is undergoing a transformative phase with ongoing research and development efforts aimed at enhancing the efficacy and applicability of vaccines. This commitment to innovation is crucial for addressing the evolving challenges in disease prevention and maintaining the health of aquatic organisms in large-scale aquaculture operations.
Adjuvants play a pivotal role in vaccine formulations by enhancing the body's immune response to the targeted pathogen. Ongoing research efforts are focused on identifying and developing more effective adjuvants specifically tailored for aquatic species. These adjuvants boost the immune response and contribute to the overall efficiency of the vaccine.
Diversity of aquatic species cultivated in commercial aquaculture necessitates species-specific vaccine formulations. Ongoing R&D efforts are directed towards creating vaccines tailored to the unique immunological profiles of different fish, shrimp, and mollusk species. This approach ensures that vaccines provide optimal protection against specific pathogens affecting each species.
“Growing Adoption of Recirculating Aquaculture Systems”
Adoption of recirculating aquaculture systems (RASs) represents a significant shift in the aquaculture industry, and its influence is reverberating across various facets, including disease prevention through the high demand for vaccines. RAS is a sustainable aquaculture practice that involves the use of closed-system setups to cultivate aquatic organisms, offering several environmental and operational advantages.
Unlike traditional open pond systems, RAS allows for meticulous control over water quality parameters, including temperature, oxygen levels, and waste management. These controlled conditions provide an ideal setting for disease prevention strategies, making vaccines a critical component in maintaining the health of the aquatic stocks.
RAS is often employed in intensive aquaculture systems where higher stocking densities are feasible. In such setups, the health management of aquatic organisms becomes paramount. Vaccines play a crucial role in maintaining optimal health and minimizing the impact of stress-related factors that can be exacerbated in intensive production settings
What’s Hurting the Profits of Commercial Aquaculture Vaccine Producers?
“Lengthy Regulatory Approval Timelines Delaying Vaccine Introduction”
The regulatory approval processes for aquaculture vaccines are characterized by extensive and time-consuming evaluations. From initial preclinical testing to field trials and eventual market authorization, the timelines can extend over several years. Furthermore, the prolonged approval process delays the commercialization of vaccines, hindering timely access to innovative disease-prevention solutions for aquaculture operators.
“High Research and Development Costs”
The intricate regulatory framework necessitates comprehensive research and development efforts to generate the data required for approval submissions. The costs associated with conducting extensive clinical trials and meeting regulatory standards are contributing to the overall financial burden on vaccine manufacturers. For smaller or newer entrants, these high costs can act as a deterrent, limiting their ability to bring innovative vaccines to market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How Can New Companies Position Themselves Profitably in This Market?
“Focus on Developing Expertise in Species-specific Aquaculture Vaccines”
Newcomers should differentiate themselves by specializing in species-specific aquaculture vaccines. Focusing on a niche market allows for in-depth understanding and expertise, making it easier to tailor products to the unique needs of customers. Specialization enhances the perceived value of the vaccines and attracts customers seeking precisely targeted solutions.
“Collaboration with Research Institutions to Expand Market Reach”
Building collaborative partnerships with research institutions and universities can provide new entrants with access to cutting-edge research and development capabilities. By leveraging external expertise, new companies can enhance the scientific foundation of their vaccine formulations, potentially leading to innovative and effective solutions that stand out in the market.
Country-wise Analysis
Strong emphasis on biosecurity, technological advancements, and high consumption of seafood are collectively driving the commercial aquaculture vaccine demand in the United States, Germany, and Japan.
What is Driving Commercial Aquaculture Vaccine Demand in the United States?
“Stringent Biosecurity Measures Boosting Demand for Modern Commercial Aquaculture Vaccines”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 42 Million |
| Growth Rate (2024 to 2034) | 7% CAGR |
| Projected Value (2034F) | US$ 83 Million |
The United States is projected to hold 72.2% North American commercial aquaculture vaccine market share by 2034. The United States places a strong emphasis on biosecurity in aquaculture operations. The need to prevent and control diseases is a significant driver boosting the demand for commercial aquaculture vaccines.
Growing consumer awareness and demand for sustainably sourced seafood is further driving the adoption of sustainable aquaculture practices in the United States, thus boosting aquaculture vaccine sales.
Why is Demand for Commercial Aquaculture Vaccines High in Germany?
“Strong Emphasis on Sustainable and Ethical Food Production”
Germany places a high value on sustainable and ethical food production. Demand for commercial aquaculture vaccines aligns with this focus, as vaccines are instrumental in preventing diseases without resorting to excessive use of antibiotics. Sustainable aquaculture practices, including the use of vaccines, resonate with German consumers' preferences for responsibly sourced seafood. Germany's robust research and innovation landscape are also contributing to advancements in aquaculture vaccine technologies.
Why are Commercial Aquaculture Vaccine Suppliers Attracted to Japan?
“High Seafood Consumption and Government Support for Aquaculture”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 16 Million |
| Growth Rate (2024 to 2034) | 7.3% CAGR |
| Projected Value (2034F) | US$ 32 Million |
Japan has a longstanding tradition of seafood consumption, and aquaculture plays a crucial role in meeting the demand. With high seafood consumption comes a pressing need for disease prevention in aquaculture operations. Commercial aquaculture vaccines are in demand to ensure a stable and healthy supply of seafood to meet consumer preferences.
The Japanese government is actively supporting the development of the aquaculture industry to reduce dependence on wild-caught fish. This support includes initiatives to enhance disease prevention measures, creating a conducive environment for the adoption of commercial aquaculture vaccines.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
As per this new analysis by Fact.MR, a market research and competitive intelligence provider, the increasing demand for inactivated commercial aquaculture vaccines is driven by their safety profile, species-specific formulations, consistent efficacy, and regulatory advantages. These attributes position inactivated vaccines as a preferred choice for aquaculture operators seeking effective and reliable disease prevention solutions while adhering to high standards of safety and environmental responsibility.
Why are Inactivated Commercial Aquaculture Vaccines Widely Preferred?
“Inactivated Vaccines Eliminating Live Agent Risks for Reliable Disease Prevention”
| Attribute | Inactivated Commercial Aquaculture Vaccines |
|---|---|
| Segment Value (2024E) | US$ 217.4 Million |
| Growth Rate (2024 to 2034) | 6.4% CAGR |
| Projected Value (2034F) | US$ 404.1 Million |
Inactivated vaccines provide a safe and residue-free alternative, aligning with stringent food safety standards. Inactivated vaccines involve the use of killed pathogens, eliminating the risk of live agents causing unwanted infections or unintended effects in vaccinated aquatic organisms. This safety aspect is particularly crucial in aquaculture, where concerns about residue presence in seafood products are high. Furthermore, this is also important in closed-system setups, such as RASs, where biosecurity measures are of utmost importance.
Compared to live vaccines, inactivated vaccines often provide a more consistent level of efficacy. The process of inactivation ensures that the vaccine's potency remains stable over time and under various storage conditions. This consistency is essential for reliable disease prevention and management in aquaculture operations.
Competitive Landscape
Leading producers of commercial aquaculture vaccines are strategically diversifying their product portfolios to address a broad spectrum of aquatic species and pathogens. This approach enables them to cater to the diverse needs of aquaculture producers, providing vaccines tailored to specific species and diseases. A comprehensive product range enhances market competitiveness and also allows manufacturers to capture large market shares.
Key Segments of Commercial Aquaculture Vaccine Market Research
-
By Vaccine Type:
- Inactivated
- Attenuated
- Subunit
- DNA
-
By Pathogen:
- Bacteria
- Virus
-
By Species:
- Salmon
- Tilapia
- Trout
- Sea Bass
- Carp
- Turbot
- Bream
- Others
-
By Route of Administration:
- Intraperitoneal
- Intramuscular
- Immersion
- Oral
-
By End User:
- Fish Farming Companies
- Fish Veterinary Clinics
- Aquatic Research Institutes
-
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Vaccine Type Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.1.1. Rise in Expenditure 4.1.2. Increased Per Capita Expenditure 4.2. Forecast Factors - Relevance & Impact 4.2.1. Vaccine Type in Pipeline 4.2.2. Regulatory Scenario 4.2.3. Mergers and Acquisitions 4.2.4. Collaborative Agreements 4.2.5. Value Chain 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity Analysis 4.4. COVID19 Crisis Analysis 4.4.1. Current COVID19 Statistics and Probable Future Impact 4.4.2. Current GDP Projection and Probable Impact 4.4.3. Current Economic Projection as Compared to 2008 Economic analysis 4.4.4. COVID19 and Impact Analysis 4.4.4.1. Revenue By Vaccine Type 4.4.4.2. Revenue By Species 4.4.4.3. Revenue By Pathogen 4.4.4.4. Revenue By Route of Administration 4.4.4.5. Revenue By End User 4.4.4.6. Revenue By Country 4.4.5. 2020 Market Scenario 4.4.6. Quarter by Quarter Forecast 4.4.7. Projected Recovery Quarter 4.4.8. Recovery Scenario - Short term, Midterm and Long Term Impact 5. Market Context 5.1. Adoption and Usage Analysis 5.2. Market Evolution 5.3. Vaccine Type Vs Species Matrix 5.4. Regulatory Scenario 5.5. Parent Market Analysis 5.6. Key Promotional Strategies by Market Players 6. Global Market - Pricing Analysis 6.1. Regional Pricing Analysis By Vaccine Type 6.2. Pricing Break-up 6.2.1. Manufacturer Level Pricing 6.2.2. Distributor Level Pricing 6.3. Global Average Pricing Analysis Benchmark 7. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034 7.1. Historical Market Value (US$ Mn) Analysis, 2018 to 2023 7.2. Current and Future Market Value (US$ Mn) Projections, 2024 to 2034 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type 8.1. Introduction / Key Findings 8.2. Historical Market Route of Administration (US$ Mn) Analysis By Vaccine Type, 2018 to 2023 8.3. Current and Future Market Route of Administration (US$ Mn) Analysis and Forecast By Vaccine Type, 2024 to 2034 8.3.1. Inactivated 8.3.2. Attenuated 8.3.3. Subunit 8.3.4. DNA 8.4. Market Attractiveness Analysis By Vaccine Type 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Pathogen 9.1. Introduction / Key Findings Pathogen Route of Administration, 2018 to 2023 9.2. Current and Future Market Route of Administration (US$ Mn) Analysis and Forecast By Pathogen, 2024 to 2034 9.2.1. Bacteria 9.2.2. Virus 9.3. Market Attractiveness Analysis By Pathogen 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Species 10.1. Introduction / Key Findings Species Route of Administration, 2018 to 2023 10.2. Current and Future Market Route of Administration (US$ Mn) Analysis and Forecast By Species, 2024 to 2034 10.2.1. Salmon 10.2.2. Tilapia 10.2.3. Trout 10.2.4. Sea Bass 10.2.5. Carp 10.2.6. Turbot 10.2.7. Bream 10.2.8. Others 10.3. Market Attractiveness Analysis By Species 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Route of Administration 11.1. Introduction / Key Findings Route of Administration, 2018 to 2023 11.2. Current and Future Market Route of Administration (US$ Mn) Analysis and Forecast By Route of Administration, 2024 to 2034 11.2.1. Intraperitoneal 11.2.2. Intramuscular 11.2.3. Immersion 11.2.4. Oral 11.3. Market Attractiveness Analysis By Route of Administration 12. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by End User 12.1. Introduction / Key Findings 12.2. Historical Market Route of Administration (US$ Mn) Analysis By End User, 2018 to 2023 12.3. Current and Future Market Route of Administration (US$ Mn) Analysis and Forecast By End User, 2024 to 2034 12.3.1. Fish Farming Companies 12.3.2. Fish Veterinary Clinics 12.3.3. Aquatic Research Institutes 12.4. Market Attractiveness Analysis By End User 13. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region 13.1. Introduction 13.2. Historical Market Route of Administration (US$ Mn) Analysis By Region, 2018 to 2023 13.3. Current Market Route of Administration (US$ Mn) Analysis and Forecast By Region, 2024 to 2034 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa (MEA) 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Route of Administration (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 14.3. Market Route of Administration (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 14.3.1. By Country 14.3.1.1. United States 14.3.1.2. Canada 14.3.2. By Vaccine Type 14.3.3. By Pathogen 14.3.4. By Species 14.3.5. By Route of Administration 14.3.6. By End User 14.4. Market Attractiveness Analysis 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 15. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Route of Administration (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 15.3. Market Route of Administration (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. United Kingdom 15.3.1.5. Spain 15.3.1.6. Rest of Europe 15.3.2. By Vaccine Type 15.3.3. By Pathogen 15.3.4. By Species 15.3.5. By Route of Administration 15.3.6. By End User 15.4. Market Attractiveness Analysis 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 16. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Route of Administration (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 16.3. Market Route of Administration (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. GCC Countries 16.3.1.2. South Africa 16.3.1.3. Rest of Middle East and Africa 16.3.2. By Vaccine Type 16.3.3. By Pathogen 16.3.4. By Species 16.3.5. By Route of Administration 16.3.6. By End User 16.4. Market Attractiveness Analysis 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 17. Rest of the World Market Analysis 2018 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Route of Administration (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 17.3. Market Route of Administration (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 17.3.1. By Vaccine Type 17.3.2. By Pathogen 17.3.3. By Species 17.3.4. By Route of Administration 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 18. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. United States Market Analysis 18.2.1. By Vaccine Type 18.2.2. By Pathogen 18.2.3. By Species 18.2.4. By Route of Administration 18.2.5. By End User 18.3. Canada Market Analysis 18.3.1. By Vaccine Type 18.3.2. By Pathogen 18.3.3. By Species 18.3.4. By Route of Administration 18.3.5. By End User 18.4. United Kingdom Market Analysis 18.4.1. By Vaccine Type 18.4.2. By Pathogen 18.4.3. By Species 18.4.4. By Route of Administration 18.4.5. By End User 18.5. Germany Market Analysis 18.5.1. By Vaccine Type 18.5.2. By Pathogen 18.5.3. By Species 18.5.4. By Route of Administration 18.5.5. By End User 18.6. France Market Analysis 18.6.1. By Vaccine Type 18.6.2. By Pathogen 18.6.3. By Species 18.6.4. By Route of Administration 18.6.5. By End User 18.7. Italy Market Analysis 18.7.1. By Vaccine Type 18.7.2. By Pathogen 18.7.3. By Species 18.7.4. By Route of Administration 18.7.5. By End User 18.8. Spain Market Analysis 18.8.1. By Vaccine Type 18.8.2. By Pathogen 18.8.3. By Species 18.8.4. By Route of Administration 18.8.5. By End User 18.8.6. By End User 18.9. GCC Countries Market Analysis 18.9.1. By Vaccine Type 18.9.2. By Pathogen 18.9.3. By Species 18.9.4. By Route of Administration 18.9.5. By End User 18.10. South Africa Market Analysis 18.10.1. By Vaccine Type 18.10.2. By Pathogen 18.10.3. By Species 18.10.4. By Route of Administration 18.10.5. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 19.4. Market Presence Analysis 19.4.1. By Regional footprint of Players 19.4.2. Vaccine Type foot print by Players 19.4.3. Channel Foot Print by Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Hipra 20.3.1.1. Overview 20.3.1.2. Vaccine Type Portfolio 20.3.1.3. Analyst Commentary 20.3.1.4. Key Financials 20.3.1.5. Recent Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Vaccine Type Strategy 20.3.1.7.3. Channel Strategy 20.3.2. Ceva Sante Animale 20.3.2.1. Overview 20.3.2.2. Vaccine Type Portfolio 20.3.2.3. Analyst Commentary 20.3.2.4. Key Financials 20.3.2.5. Recent Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Vaccine Type Strategy 20.3.2.7.3. Channel Strategy 20.3.3. Vaxxinova 20.3.3.1. Overview 20.3.3.2. Vaccine Type Portfolio 20.3.3.3. Analyst Commentary 20.3.3.4. Key Financials 20.3.3.5. Recent Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Vaccine Type Strategy 20.3.3.7.3. Channel Strategy 20.3.4. Zoetis Inc. (PharmaQ) 20.3.4.1. Overview 20.3.4.2. Vaccine Type Portfolio 20.3.4.3. Analyst Commentary 20.3.4.4. Key Financials 20.3.4.5. Recent Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Vaccine Type Strategy 20.3.4.7.3. Channel Strategy 20.3.5. Merck Animal Health 20.3.5.1. Overview 20.3.5.2. Vaccine Type Portfolio 20.3.5.3. Analyst Commentary 20.3.5.4. Key Financials 20.3.5.5. Recent Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Vaccine Type Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Elanco Animal Health 20.3.6.1. Overview 20.3.6.2. Vaccine Type Portfolio 20.3.6.3. Analyst Commentary 20.3.6.4. Key Financials 20.3.6.5. Recent Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Vaccine Type Strategy 20.3.6.7.3. Channel Strategy 20.3.7. AquaBounty Technologies 20.3.7.1. Overview 20.3.7.2. Vaccine Type Portfolio 20.3.7.3. Analyst Commentary 20.3.7.4. Key Financials 20.3.7.5. Recent Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Vaccine Type Strategy 20.3.7.7.3. Channel Strategy 20.3.8. Benchmark Holdings plc 20.3.8.1. Overview 20.3.8.2. Vaccine Type Portfolio 20.3.8.3. Analyst Commentary 20.3.8.4. Key Financials 20.3.8.5. Recent Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Vaccine Type Strategy 20.3.8.7.3. Channel Strategy 20.3.9. Tecnovax SA 20.3.9.1. Overview 20.3.9.2. Vaccine Type Portfolio 20.3.9.3. Analyst Commentary 20.3.9.4. Key Financials 20.3.9.5. Recent Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Vaccine Type Strategy 20.3.9.7.3. Channel Strategy 20.3.10. Bluestar Adisseo Co. 20.3.10.1. Overview 20.3.10.2. Vaccine Type Portfolio 20.3.10.3. Analyst Commentary 20.3.10.4. Key Financials 20.3.10.5. Recent Developments 20.3.10.6. Sales Footprint 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategy 20.3.10.7.2. Vaccine Type Strategy 20.3.10.7.3. Channel Strategy 20.3.11. Genentech Biotechnology 20.3.11.1. Overview 20.3.11.2. Vaccine Type Portfolio 20.3.11.3. Analyst Commentary 20.3.11.4. Key Financials 20.3.11.5. Recent Developments 20.3.11.6. Sales Footprint 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategy 20.3.11.7.2. Vaccine Type Strategy 20.3.11.7.3. Channel Strategy 20.3.12. Hendrix Genetics BV 20.3.12.1. Overview 20.3.12.2. Vaccine Type Portfolio 20.3.12.3. Analyst Commentary 20.3.12.4. Key Financials 20.3.12.5. Recent Developments 20.3.12.6. Sales Footprint 20.3.12.7. Strategy Overview 20.3.12.7.1. Marketing Strategy 20.3.12.7.2. Vaccine Type Strategy 20.3.12.7.3. Channel Strategy 20.3.13. Nisseiken Co. Ltd. 20.3.13.1. Overview 20.3.13.2. Vaccine Type Portfolio 20.3.13.3. Analyst Commentary 20.3.13.4. Key Financials 20.3.13.5. Recent Developments 20.3.13.6. Sales Footprint 20.3.13.7. Strategy Overview 20.3.13.7.1. Marketing Strategy 20.3.13.7.2. Vaccine Type Strategy 20.3.13.7.3. Channel Strategy 20.3.14. Europharma AS 20.3.14.1. Overview 20.3.14.2. Vaccine Type Portfolio 20.3.14.3. Analyst Commentary 20.3.14.4. Key Financials 20.3.14.5. Recent Developments 20.3.14.6. Sales Footprint 20.3.14.7. Strategy Overview 20.3.14.7.1. Marketing Strategy 20.3.14.7.2. Vaccine Type Strategy 20.3.14.7.3. Channel Strategy 20.3.15. Fish Vet Group 20.3.15.1. Overview 20.3.15.2. Vaccine Type Portfolio 20.3.15.3. Analyst Commentary 20.3.15.4. Key Financials 20.3.15.5. Recent Developments 20.3.15.6. Sales Footprint 20.3.15.7. Strategy Overview 20.3.15.7.1. Marketing Strategy 20.3.15.7.2. Vaccine Type Strategy 20.3.15.7.3. Channel Strategy 20.3.16. Novartis Animal Health 20.3.16.1. Overview 20.3.16.2. Vaccine Type Portfolio 20.3.16.3. Analyst Commentary 20.3.16.4. Key Financials 20.3.16.5. Recent Developments 20.3.16.6. Sales Footprint 20.3.16.7. Strategy Overview 20.3.16.7.1. Marketing Strategy 20.3.16.7.2. Vaccine Type Strategy 20.3.16.7.3. Channel Strategy 20.3.17. Intervet Inc. 20.3.17.1. Overview 20.3.17.2. Vaccine Type Portfolio 20.3.17.3. Analyst Commentary 20.3.17.4. Key Financials 20.3.17.5. Recent Developments 20.3.17.6. Sales Footprint 20.3.17.7. Strategy Overview 20.3.17.7.1. Marketing Strategy 20.3.17.7.2. Vaccine Type Strategy 20.3.17.7.3. Channel Strategy 20.3.18. Provaxs Biotek Inc. 20.3.18.1. Overview 20.3.18.2. Vaccine Type Portfolio 20.3.18.3. Analyst Commentary 20.3.18.4. Key Financials 20.3.18.5. Recent Developments 20.3.18.6. Sales Footprint 20.3.18.7. Strategy Overview 20.3.18.7.1. Marketing Strategy 20.3.18.7.2. Vaccine Type Strategy 20.3.18.7.3. Channel Strategy 20.3.19. Vaki Aquaculture Systems Ltd. 20.3.19.1. Overview 20.3.19.2. Vaccine Type Portfolio 20.3.19.3. Analyst Commentary 20.3.19.4. Key Financials 20.3.19.5. Recent Developments 20.3.19.6. Sales Footprint 20.3.19.7. Strategy Overview 20.3.19.7.1. Marketing Strategy 20.3.19.7.2. Vaccine Type Strategy 20.3.19.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 02: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 03: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 04: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 05: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 06: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration Age Group
Table 07: Global Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
Table 08: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 10: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 11: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 12: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 13: North America Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 14: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 16: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 17: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 18: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 19: Europe Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 20: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 22: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 23: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 24: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 25: Middle East and Africa Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 26: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Vaccine Type
Table 27: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Species
Table 28: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Pathogen
Table 29: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 30: Rest of the World Market Route of Administration (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 02: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 03: Global Market Share Analysis (%), By Vaccine Type, 2024 to 2034
Figure 04: Global Market Y-o-Y Analysis (%), By Vaccine Type, 2024 to 2034
Figure 05: Global Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 06: Global Market Share Analysis (%), By Pathogen, 2024 to 2034
Figure 07: Global Market Y-o-Y Analysis (%), By Pathogen, 2024 to 2034
Figure 08: Global Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 09: Global Market Share Analysis (%), By Species, 2024 to 2034
Figure 10: Global Market Y-o-Y Analysis (%), By Species, 2024 to 2034
Figure 11: Global Market Attractiveness Analysis By Species, 2024 to 2034
Figure 12: Global Market Share Analysis (%), By Route of Administration, 2024 to 2034
Figure 13: Global Market Y-o-Y Analysis (%), By Route of Administration, 2024 to 2034
Figure 14: Global Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 15: Global Market Share Analysis (%), By End User, 2024 to 2034
Figure 16: Global Market Y-o-Y Analysis (%), By End User , 2024 to 2034
Figure 17: Global Market Attractiveness Analysis, By End User, 2024 to 2034
Figure 18: Global Market Share Analysis (%), By Route of Administration Age Group, 2024 to 2034
Figure 19: Global Market Y-o-Y Analysis (%), By Route of Administration Age Group, 2024 to 2034
Figure 20: Global Market Attractiveness Analysis By Route of Administration Age Group, 2024 to 2034
Figure 21: Global Market Share Analysis (%), By Region, 2024 to 2034
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 23: Global Market Attractiveness Analysis, By Region, 2024 to 2034
Figure 24: North America Market Value Share, By Vaccine Type, 2024 (E)
Figure 25: North America Market Value Share, By Speciess 2024 (E)
Figure 26: North America Market Value Share, By Pathogen, 2024 (E)
Figure 27: North America Market Value Share, By Route of Administration, 2024 (E)
Figure 28: North America Market Value Share, By End User, 2024 (E)
Figure 29: North America Market Value Share, By Country, 2024 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 31: North America Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis By Species, 2024 to 2034
Figure 33: North America Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 34: North America Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis By End User, 2024 to 2034
Figure 36: North America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 37: Europe Market Value Share, By Vaccine Type, 2024 (E)
Figure 38: Europe Market Value Share, By Speciess 2024 (E)
Figure 39: Europe Market Value Share, By Pathogen, 2024 (E)
Figure 40: Europe Market Value Share, By Route of Administration, 2024 (E)
Figure 41: Europe Market Value Share, By End User, 2024 (E)
Figure 42: Europe Market Value Share, By Country, 2024 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 44: Europe Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 45: Europe Market Attractiveness Analysis By Species, 2024 to 2034
Figure 46: Europe Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 47: Europe Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 48: Europe Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 49: Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 50: Middle East and Africa Market Value Share, By Vaccine Type, 2024 (E)
Figure 51: Middle East and Africa Market Value Share, By Species, 2024 (E)
Figure 52: Middle East and Africa Market Value Share, By Pathogen, 2024 (E)
Figure 53: Middle East and Africa Market Value Share, By Route of Administration, 2024 (E)
Figure 54: Middle East and Africa Market Value Share, By End User, 2024 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 57: Middle East and Africa Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 58: Middle East and Africa Market Attractiveness Analysis By Species, 2024 to 2034
Figure 59: Middle East and Africa Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 60: Middle East and Africa Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 61: Middle East and Africa Market Attractiveness Analysis By End User, 2024 to 2034
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2024 to 2034
Figure 63: Rest of the World Market Value Share, By Vaccine Type, 2024 (E)
Figure 64: Rest of the World Market Value Share, By Speciess 2024 (E)
Figure 65: Rest of the World Market Value Share, By Pathogen, 2024 (E)
Figure 66: Rest of the World Market Value Share, By Route of Administration, 2024 (E)
Figure 67: Rest of the World Market Value Share, By End User, 2024 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 69: Rest of the World Market Attractiveness Analysis By Vaccine Type, 2024 to 2034
Figure 70: Rest of the World Market Attractiveness Analysis By Species, 2024 to 2034
Figure 71: Rest of the World Market Attractiveness Analysis By Pathogen, 2024 to 2034
Figure 72: Rest of the World Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 73: Rest of the World Market Attractiveness Analysis By End User, 2024 to 2034
Figure 74: United States Market Value Share, By Vaccine Type, 2024 to 2034
Figure 75: United States Market Value Share, By Species, 2024 to 2034
Figure 76: United States Market Value Share, By Pathogen, 2024 to 2034
Figure 77: United States Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 78: United States Market Value Share, By End User, 2024 to 2034
Figure 79: United States Market Value Analysis (US$ Mn), 2024 to 2034
Figure 80: Canada Market Value Share, By Vaccine Type, 2024 to 2034
Figure 81: Canada Market Value Share, By Species, 2024 to 2034
Figure 82: Canada Market Value Share, By Pathogen, 2024 to 2034
Figure 83: Canada Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 84: Canada Market Value Share, By End User, 2024 to 2034
Figure 85: Canada Market Value Analysis (US$ Mn), 2024 to 2034
Figure 86: United Kingdom Market Value Share, By Vaccine Type, 2024 to 2034
Figure 87: United Kingdom Market Value Share, By Species, 2024 to 2034
Figure 88: United Kingdom Market Value Share, By Pathogen, 2024 to 2034
Figure 89: United Kingdom Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 90: United Kingdom Market Value Share, By End User, 2024 to 2034
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2024 to 2034
Figure 92: Germany Market Value Share, By Vaccine Type, 2024 to 2034
Figure 93: Germany Market Value Share, By Species, 2024 to 2034
Figure 94: Germany Market Value Share, By Pathogen, 2024 to 2034
Figure 95: Germany Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 96: Germany Market Value Share, By End User, 2024 to 2034
Figure 97: Germany Market Value Analysis (US$ Mn), 2024 to 2034
Figure 98: France Market Value Share, By Vaccine Type, 2024 to 2034
Figure 99: France Market Value Share, By Species, 2024 to 2034
Figure 100: France Market Value Share, By Pathogen, 2024 to 2034
Figure 101: France. Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 102: France Market Value Share, By End User, 2024 to 2034
Figure 103: France Market Value Analysis (US$ Mn), 2024 to 2034
Figure 104: Italy Market Value Share, By Vaccine Type, 2024 to 2034
Figure 105: Italy Market Value Share, By Species, 2024 to 2034
Figure 106: Italy Market Value Share, By Pathogen, 2024 to 2034
Figure 107: Italy Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 108: Italy Market Value Share, By End User, 2024 to 2034
Figure 109: Italy Market Value Analysis (US$ Mn), 2024 to 2034
Figure 110: Spain Market Value Share, By Vaccine Type, 2024 to 2034
Figure 111: Spain Market Value Share, By Species, 2024 to 2034
Figure 112: Spain Market Value Share, By Pathogen, 2024 to 2034
Figure 113: Spain Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 114: Spain Market Value Share, By End User, 2024 to 2034
Figure 115: Spain Market Value Analysis (US$ Mn), 2024 to 2034
Figure 116: GCC Countries. Market Value Share, By Vaccine Type, 2024 to 2034
Figure 117: GCC Countries Market Value Share, By Species, 2024 to 2034
Figure 118: GCC Countries Market Value Share, By Pathogen, 2024 to 2034
Figure 119: GCC Countries Market Value Share, By Route of Administration, 2024 to 2034
Figure 120: GCC Countries Market Value Share, By End User, 2024 to 2034
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2024 to 2034
Figure 122: South Africa Market Value Share, By Vaccine Type, 2024 to 2034
Figure 123: South Africa Market Value Share, By Species, 2024 to 2034
Figure 124: South Africa Market Value Share, By Pathogen, 2024 to 2034
Figure 125: South Africa Market Value Share, By Route of Administration Age Group, 2024 to 2034
Figure 126: South Africa Market Value Share, By End User, 2024 to 2034
Figure 127: South Africa Market Value Analysis (US$ Mn), 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the commercial aquaculture vaccine market?
The global commercial aquaculture vaccine market is estimated at US$ 305.2 million in 2024.
What is the sales value of commercial aquaculture vaccines in Japan?
Sales of commercial aquaculture vaccines are pegged at US$ 16 million for 2024.
What is the demand projection for commercial aquaculture vaccines for 2034?
Global commercial aquaculture vaccine demand is forecasted to reach a valuation of US$ 584.3 million by 2034-end.
At what rate are commercial aquaculture vaccine sales predicted to increase?
Sales of commercial aquaculture vaccines are projected to rise at a CAGR of 6.7% from 2024 to 2034.
Which vaccine type is projected to account for higher demand?
Revenue from inactivated commercial aquaculture vaccines is forecasted to reach US$ 404.1 million by 2034-end.
Who are the key producers of commercial aquaculture vaccines?
Some of the leading companies are Merck & Co., Inc., Hipra, Technovax, and Elanco.
Commercial Aquaculture Vaccine Market